The present invention relates to a method and means for promoting or improving renal function. Specifically, the present invention relates to a composition for promoting or improving renal function, the composition containing turmeric extract as an active ingredient.
The present invention relates to a method and means for improving insulin resistance. Specifically, the present invention relates to a composition for improving insulin resistance, the composition containing turmeric extract as an active ingredient.
The present invention addresses the problem of providing a composition for improving the immunostimulatory effect of lactic acid bacteria, preferably Lactobacillus plantarum L-137. The problem is solved by this composition containing turmeric extract.
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
The present invention pertains to a β-secretase inhibitor. The present invention also pertains to a composition for preventing or treating dementia. Specifically, the present invention pertains to a β-secretase containing at least one of turmeronol A, turmeronol B, and bisacron as an active ingredient.
A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
An object of the present invention is to provide a baked food which has a good flavor and texture while being substantially free of proteins such as milk, eggs and wheat. The present invention provides a dough for baked food comprising: water, a fat and oil, a starch, cyclodextrin and a predetermined water-soluble gelling agent, wherein the dough is substantially free of proteins, as well as a baked food obtained by baking the dough for baked food.
It is an object of the present invention to provide a liquid emulsion composition which has a good smooth texture, without containing protein such as egg, and the present invention provides a liquid emulsion composition containing water, 50 mass % or less of an oil and fat, a cyclodextrin, a water-soluble gelling agent, and a dextrin.
A23L 29/269 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
A23L 29/238 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
A23L 29/244 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
A23L 29/256 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
A23L 29/262 - CelluloseDerivatives thereof, e.g. ethers
A23L 35/00 - Foods or foodstuffs not provided for in groups Preparation or treatment thereof
7.
COMPOSITION FOR INHIBITION OF DIFFERENTIATION OF OSTEOCLAST PRECURSOR CELLS INTO OSTEOCLASTS, AND COMPOSITION FOR IMPROVING BONE METABOLISM
A problem to be solved by the present invention is to provide a composition (1) for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting bone density reduction, the composition (1) including a culture supernatant or a processed product thereof, the culture supernatant being obtainable by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof, or a composition (2) for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting bone density reduction, the composition (2) including Lactobacillus plantarum strain L-137 (Lactobacillus plantarum L-137) or a processed product thereof. These compositions solve the problem.
The purpose of the present invention is to provide a novel means that enables enhancement and/or prolongation of the effect of an active ingredient. Provided is a retaining agent to be used for retaining an active ingredient, the retaining agent comprising an oil-in-water type emulsion containing water, a hydrophobic substance, cyclodextrin and a thickening polysaccharide.
The present invention addresses the problem of providing a composition for improving fatigue, sleeping disorders or eye strain and menopausal symptoms. The problem is solved by a composition containing Lactobacillus plantarum L-137.
[Problem] The present invention addresses the problem of providing a composition for improving the intestinal barrier function and/or strengthening intestinal epithelial tight junctions that contains Lactobacillus plantarum L-137 or a processed product thereof. [Solution] This problem is solved by means of the abovementioned composition.
It is an object of the present invention to provide a mayonnaise-style dressing which has physical properties comparable to those of mayonnaise, without containing protein such as egg, and the present invention relates to a mayonnaise-style dressing obtained by mixing water, an oil or fat, a cyclodextrin, and a water-soluble gelling agent to obtain a mixture, and adding an emulsifying agent to the mixture and further mixing the mixture and the emulsifying agent.
A23D 7/005 - Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
A23D 7/01 - Other fatty acid esters, e.g. phosphatides
A23L 29/10 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing emulsifiers
A23L 29/269 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
12.
COMPOSITION FOR ENHANCING ADRENOMEDULLIN GENE EXPRESSION
The present invention provides a composition having an action to enhance adrenomedullin gene expression. One or more embodiments of the present invention relate to a composition for enhancing adrenomedullin gene expression containing a TRPV1 agonist and a TRPA1 agonist as active ingredients. The TRPV1 agonist can be, for example, at least one selected from capsaicin, 6-shogaol, 6-gingerol and piperine. The TRPA1 agonist can be, for example, at least one selected from allyl isothiocyanate, cinnamaldehyde, diallyl disulfide, ASP7663 and oxylipin.
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 43/00 - Drugs for specific purposes, not provided for in groups
An object of the present invention is to provide an emulsified composition containing fat and oil, water, and cyclodextrin, which has high emulsion stability and a good feeling of use when applied to the skin. Provided is an emulsified composition for skin containing water, fat and oil, cyclodextrin, and a prescribed water-soluble gelling agent.
A problem to be solved by the present invention is to provide one or more selected from (1) a feed comprising Lactobacillus plantarum strain L-137 or a processed product thereof and a fatty acid or a salt thereof, (2) a composition for enhancing IL-12 production, comprising Lactobacillus plantarum strain L-137 or a processed product thereof and a fatty acid or a salt thereof, (3) a composition for immunostimulation, comprising Lactobacillus plantarum strain L-137 or a processed product thereof and a fatty acid or a salt thereof, and (4) a composition for bacteriostasis, comprising Lactobacillus plantarum strain L-137 or a processed product thereof and a fatty acid or a salt thereof. The problem is solved by providing one or more of the feed or the compositions.
The purpose of the present invention is to provide an emulsion composition in which emulsion is not disrupted even when applied under high-temperature conditions, the emulsion composition having high heat resistance and exceptional emulsion stability, and containing an oil and fat, water, cyclodextrin, and a water-soluble gelling agent. The present invention provides an acidic emulsion composition containing water, an oil and fat, cyclodextrin, a water-soluble gelling agent, and a water-soluble organic solvent.
A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
A23L 29/10 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing emulsifiers
A23L 29/20 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
The purpose of the present invention is to provide an emulsion composition that has high emulsion stability and that contains fats and oils, water, cyclodextrin, and a water-soluble gelling agent. Provided is an emulsion composition containing water, fats and oils, cyclodextrin, and a prescribed water-soluble gelling agent. The ratio of the blending amount of the fats and oils to the total blending amount of the cyclodextrin and the water-soluble gelling agent is, in terms of the mass ratio, in the range of 1 or more to less than 9 : 9 or less to more than 1 (the blending amount of the fats and oils : the total blending amount of the cyclodextrin and the water-soluble gelling agent).
The purpose of the present invention is to provide a liquid emulsion composition that has a good smooth texture without containing a protein such as egg or the like, and provided is a liquid emulsion composition that contains water, 50 mass% or less of fat and oil, cyclodextrin, a water-soluble gelling agent, and dextrin.
A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
A23L 29/238 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
A23L 29/244 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
A23L 29/256 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
A23L 29/262 - CelluloseDerivatives thereof, e.g. ethers
A23L 29/269 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
A23L 35/00 - Foods or foodstuffs not provided for in groups Preparation or treatment thereof
18.
Composition for Improving or Maintaining Quality of Life
The present invention provides a composition for improving or maintaining quality of life (QOL), comprising, as an active ingredient, a component derived from turmeric. The present invention relates to a composition for improving or maintaining QOL, comprising, as an active ingredient, at least one of turmeronol A, turmeronol B, and bisacurone. The composition of the present invention for improving or maintaining QOL may comprise 20 μg or more of turmeronol A and turmeronol B in total per daily intake, may comprise 17 μg or more of turmeronol A per daily intake, may comprise 5 μg or more of turmeronol B per daily intake, and may comprise 80 μg or more of bisacurone per daily intake.
The present invention addresses the problem of providing: (1) a composition that is for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting a reduction in bone density, and that is characterized by containing an immune cell culture supernatant obtained by culturing immune cells in the presence of a lactic acid bacterium or a treatment product of a lactic acid bacterium, or a treatment product of the composition, and (2) a composition that is for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting a reduction in bone density, and that is characterized by containing Lactobacillus plantarum L-137 strain or a treatment product thereof. The problem is solved by the compositions.
The purpose of the present invention is to provide a baked food having good flavor and texture while containing substantially no protein, such as milk, egg, or wheat. The present invention provides a baked food dough that contains water, oil and fat, starch, cyclodextrin, and a prescribed water-soluble gellant and contains substantially no protein, and provides a baked food obtained by baking the dough.
One or more embodiments of the present invention relate to a composition for improving lipid metabolism or carbohydrate metabolism, comprising a component derived from turmeric. One or more embodiments of the present invention relate to a composition for lowering blood glucose level, reducing blood hemoglobin A1c content, or increasing blood HDL-cholesterol content, a composition for treating or preventing metabolic syndrome, or a composition for improving lipid metabolism or carbohydrate metabolism, wherein each composition comprises, as an active ingredient, at least one of turmeronol A, turmeronol B, and bisacurone. Each composition may comprise 20 μg or more of turmeronol A and turmeronol B in total per daily intake, may comprise 17 μg or more of turmeronol A per daily intake, may comprise 5 μg or more of turmeronol B per daily intake, and may comprise 80 μg or more of bisacurone per daily intake.
One or more embodiments of the present invention provide a composition for inhibiting TNF-α or IL-6 production, comprising a component derived from turmeric. One or more embodiments of the present invention relate to a composition for inhibiting TNF-α or IL-6 production, comprising at least one of turmeronol A, turmeronol B, and bisacurone. The composition for inhibiting TNF-α or IL-6 production according to one or more embodiments of the present invention may comprise 20 μg or more of turmeronol A and turmeronol B in total per daily intake, may comprise 17 μg or more of turmeronol A per daily intake, may comprise 5 μg or more of turmeronol B per daily intake, and may comprise 80 μg or more of bisacurone per daily intake.
The present invention pertains an ice cream-like emulsion composition containing water, an oil/fat, cyclodextrin, trehalose, and dextrin, and aims to provide an ice cream-like emulsion composition in which an increase and growth of ice crystals during frozen storage is suppressed and which has a smooth texture.
A23G 9/34 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition characterised by carbohydrates used, e.g. polysaccharides
The purpose of the present invention is to provide a mayonnaise-style dressing having physical properties similar to those of mayonnaise, without containing protein, such as egg. The present invention relates to a mayonnaise-style dressing obtained by mixing water, oil, cyclodextrin, and a water-soluble gellant, and adding an emulsifier to the mixture.
The present disclosure provides a composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels, comprising, as an active ingredient, an ingredient derived from a turmeric.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
The present invention provides a composition that has an effect of enhancing the gene expression of adrenomedullin. One or more embodiments of the present invention pertain to a composition for enhancing adrenomedullin gene expression, said composition comprising a TRPV1 agonist and a TRPA1 agonist as active ingredients. Examples of the TRPV1 agonist include one or more selected from among capsaicin, 6-shogaol, 6-gingerol and piperine. Examples of the TRPA1 agonist include one or more selected from among allyl isothiocyanate, cinnamaldehyde, diallyl disulfide, ASP7663 and an oxylipin.
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present invention provides a composition that has an effect of enhancing the gene expression of adrenomedullin. One or more embodiments of the present invention pertain to a composition for enhancing adrenomedullin gene expression, said composition comprising a TRPV1 agonist and a TRPA1 agonist as active ingredients. Examples of the TRPV1 agonist include one or more selected from among capsaicin, 6-shogaol, 6-gingerol and piperine. Examples of the TRPA1 agonist include one or more selected from among allyl isothiocyanate, cinnamaldehyde, diallyl disulfide, ASP7663 and an oxylipin.
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present invention addresses the problem of providing at least one selected from among: (1) a feed comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof; (2) a composition for enhancing IL-12 production, the composition comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof; (3) an immunostimulatory composition comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof; and (4) a bacteriostatic composition comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof. The problem is solved by said feed or composition.
The present invention addresses the problem of providing at least one selected from among: (1) a feed comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof; (2) a composition for enhancing IL-12 production, the composition comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof; (3) an immunostimulatory composition comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof; and (4) a bacteriostatic composition comprising the Lactobacillus plantarum L-137 strain or a processed product thereof, and a fatty acid or a salt thereof. The problem is solved by said feed or composition.
The purpose of the present invention is to provide an emulsified composition containing oil/fat, water, and cyclodextrin, which has high emulsification stability and feels good to use when applied to the skin. Provided is an emulsified composition for skin, the emulsified composition containing water, oil/fat, and cyclodextrin, as well as a prescribed water-soluble gelling agent.
A Composition for Treatment, Prevention, or Amelioration of Alzheimer's Disease, a Composition for Suppression of Brain Nerve Cell Death, a Composition for Suppression of Microglia Activation Induced by Amyloid Beta Peptide, and a Composition for Suppression of PGE2, TNF-alpha, or IL-1beta Production Induced by Amyloid Beta Peptide
This invention provides a composition comprising, as an active ingredient, a turmeric-derived ingredient, which is useful for treatment, prevention, or amelioration of Alzheimer's disease. This invention relates to a composition for treatment of Alzheimer's disease, a composition for suppression of brain nerve cell death, a composition for suppression of microglia activation induced by amyloid β peptide, or a composition for suppression of PGE2, TNF-α, or IL-1β production induced by amyloid β peptide comprising, as an active ingredient, a turmeric extract extracted with at least one extraction solvent selected from water and a hydrophilic organic solvent or at least one of termeronol A and termeronol B.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The purpose of the present invention is to provide an ice cream-like aerated emulsion composition having a soft and smooth texture inherent to ice creams. The invention pertains to an ice cream-like aerated emulsion composition that comprises more than 52 mass% of water, less than 23 mass% of oil or fat, cyclodextrin and a water-soluble gelling agent and that is substantially protein-free.
A23D 7/00 - Edible oil or fat compositions containing an aqueous phase, e.g. margarines
A23G 9/32 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition
A23G 9/34 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition characterised by carbohydrates used, e.g. polysaccharides
A23G 9/46 - Aerated, foamed, cellular or porous products
33.
COMPOSITION FOR INHIBITING TNF-α OR IL-6 PRODUCTION
One or more embodiments of the present invention provide a composition for inhibiting the production of TNF-α or IL-6, said composition containing a component derived from turmeric. One or more embodiments of the present invention pertain to a composition for inhibiting the production of TNF-α or IL-6, said composition containing at least one selected from turmeronol A, turmeronol B and bisacurone. The composition for inhibiting the production of TNF-α or IL-6 according to one or more embodiments of the present invention can contain turmeronol A and turmeronol B in a total amount of 20 μg or more per daily intake, turmeronol A in an amount of 17 μg or more per daily intake, turmeronol B in an amount of 5 μg or more per daily intake, and bisacurone in an amount of 80 μg or more per daily intake.
One or more embodiments of the present invention provide a composition for inhibiting the production of TNF-a or IL-6, said composition containing a component derived from turmeric. One or more embodiments of the present invention pertain to a composition for inhibiting the production of TNF-a or IL-6, said composition containing at least one selected from turmeronol A, turmeronol B and bisacurone. The composition for inhibiting the production of TNF-a or IL-6 according to one or more embodiments of the present invention can contain turmeronol A and turmeronol B in a total amount of 20 µg or more per daily intake, turmeronol A in an amount of 17 µg or more per daily intake, turmeronol B in an amount of 5 µg or more per daily intake, and bisacurone in an amount of 80 µg or more per daily intake.
One or more embodiments of the present invention provide a composition for improving lipid metabolism or carbohydrate metabolism, said composition containing a component derived from turmeric. One or more embodiments of the present invention pertain to a composition for lowering blood glucose level, reducing blood hemoglobin A1c content or increasing blood HDL-cholesterol content, a composition for treating or preventing metabolic syndrome or a composition for improving lipid metabolism or carbohydrate metabolism, said composition containing at least one selected from turmeronol A, turmeronol B and bisacurone as an active ingredient. The aforesaid composition can contain turmeronol A and turmeronol B in a total amount of 20 µg or more per daily intake, turmeronol A in an amount of 17 µg or more per daily intake, turmeronol B in an amount of 5 µg or more per daily intake, and bisacurone in an amount of 80 µg or more per daily intake.
One or more embodiments of the present invention provide a composition for improving lipid metabolism or carbohydrate metabolism, said composition containing a component derived from turmeric. One or more embodiments of the present invention pertain to a composition for lowering blood glucose level, reducing blood hemoglobin A1c content or increasing blood HDL-cholesterol content, a composition for treating or preventing metabolic syndrome or a composition for improving lipid metabolism or carbohydrate metabolism, said composition containing at least one selected from turmeronol A, turmeronol B and bisacurone as an active ingredient. The aforesaid composition can contain turmeronol A and turmeronol B in a total amount of 20 μg or more per daily intake, turmeronol A in an amount of 17 μg or more per daily intake, turmeronol B in an amount of 5 μg or more per daily intake, and bisacurone in an amount of 80 μg or more per daily intake.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
The present invention provides a composition for lowering blood pressure, including a turmeric-derived component as an effective component. The present invention relates to a composition for lowering blood pressure, including at least one of turmeronol A, turmeronol B and bisacurone. This composition for lowering blood pressure may contain a combined total of 20 μg or more of turmeronol A and turmeronol B per daily intake, may contain 17 μg or more of turmeronol A per daily intake, may contain 5 μg or more of turmeronol B per daily intake, and may contain 80 μg or more of bisacurone per daily intake.
The present invention provides a composition for improving or maintaining of quality of life (QOL), the composition including a turmeric-derived component as an effective component. The present invention relates to a composition for improving or maintaining QOL, the composition containing at least one of turmeronol A, turmeronol B and bisacurone. This composition for improving or maintaining QOL may contain a combined total of 20 μg or more of turmeronol A and turmeronol B per daily intake, may contain 17 μg or more of turmeronol A per daily intake, may contain 5 μg or more of turmeronol B per daily intake, and 80 μg or more of bisacurone per daily intake.
The present invention provides a composition for improving or maintaining of quality of life (QOL), the composition including a turmeric-derived component as an effective component. The present invention relates to a composition for improving or maintaining QOL, the composition containing at least one of turmeronol A, turmeronol B and bisacurone. This composition for improving or maintaining QOL may contain a combined total of 20 µg or more of turmeronol A and turmeronol B per daily intake, may contain 17 µg or more of turmeronol A per daily intake, may contain 5 µg or more of turmeronol B per daily intake, and 80 µg or more of bisacurone per daily intake.
An object of the present invention is to provide a composition for promoting fibroblast proliferation and/or a composition for promoting hyaluronic acid synthase gene expression. The present invention provides a composition for promoting fibroblast proliferation and/or a composition for promoting hyaluronic acid synthase gene expression, the compositions each comprising Lactobacillus plantarum L-137.
METHOD FOR PRODUCING GRANULES CONTAINING PLANT EXTRACT, METHOD FOR PREVENTING FORMATION OF MICROPOWDER FROM GRANULES CONTAINING PLANT EXTRACT, AND METHOD FOR SUPPRESSING UNPLEASANT TASTE OF GRANULES CONTAINING PLANT EXTRACT
The purpose of the present invention is to prevent the increase in viscosity of a raw material mixture and also prevent the formation of a micropowder that may deteriorate production yield, and/or suppress an unpleasant taste inherent in a plant extract in the production of granules containing the plant extract by extrusion granulation. The present invention relates to a method for producing granules containing a plant extract, characterized by comprising the step of extrusion-granulating a raw material mixture containing the plant extract, wherein the water content in the raw material mixture is 1 to 10% (w/w) and the raw material mixture contains shellac.
To reduce bitterness in the ingestion of a turmeric-derived component-containing composition for oral ingestion which is to be masticated in the oral cavity and/or dissolved in the oral cavity. In a turmeric-derived component-containing composition for oral ingestion which is to be masticated in the oral cavity and/or dissolved in the oral cavity, the bitterness of the turmeric-derived component is reduced by adding granular calcium lactate thereto. In a chewable tablet containing a turmeric-derived component, the bitterness of the turmeric-derived component is reduced and, at the same time, such a hardness as to facilitate biting and grinding in the oral cavity is imparted by adding granular calcium lactate thereto.
The present invention provides a composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels, comprising, as an active ingredient, an ingredient derived from a turmeric.The present invention relates to a composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels, comprising, as an active ingredient, at least one of turmeronol A, turmeronol B and bisacurone. The present invention also relates to a composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels, comprising a turmeric as an active ingredient.
A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
45.
A COMPOSITION FOR TREATMENT, PREVENTION, OR AMELIORATION OF ALZHEIMER'S DISEASE, A COMPOSITION FOR SUPPRESSION OF BRAIN NERVE CELL DEATH, A COMPOSITION FOR SUPPRESSION OF MICROGLIAACTIVATION INDUCED BY AMYLOID .BETA. PEPTIDE, AND A COMPOSITION FOR SUPPRESSION OF PGE2, TNF-.ALPHA., OR IL-1.BETA. PRODUCTION INDUCED BY AMYLOID .BETA. PEPTIDE
This invention provides a composition comprising, as an active ingredient, a turmeric-derived ingredient, which is useful for treatment, prevention, or amelioration of Alzheimer's disease. This invention relates to a composition for treatment of Alzheimer's disease, a composition for suppression of brain nerve cell death, a composition for suppression of microglia activation induced by amyloid .beta. peptide, or a composition for suppression of PGE2, TNF-.alpha., or IL-1.beta. production induced by amyloid .beta. peptide comprising, as an active ingredient, a turmeric extract extracted with at least one extraction solvent selected from water and a hydrophilic organic solvent or at least one of termeronol A and termeronol B.
A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
46.
COMPOSITION FOR IMPROVING VASCULAR ENDOTHELICAL FUNCTION OR IMPROVING BLOOD FLOW IN PERIPHERAL BLOOD VESSELS
The present invention provides a composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels, the composition containing a Curcuma longa-derived ingredient as an effective ingredient. The present invention relates to a composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels, the composition containing at least one of Turmeronol A, Turmeronol B and Bisacurone as an effective ingredient. The present invention also relates to a composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels, the composition containing Curcuma longa as an effective ingredient.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
47.
COMPOSITION FOR TREATMENT, PREVENTION, OR IMPROVEMENT OF ALZHEIMER'S DISEASE, COMPOSITION FOR INHIBITING CRANIAL NERVE CELL DEATH, COMPOSITION FOR INHIBITING MICROGLIA ACTIVATION INDUCED BY AMYLOID β PEPTIDE, AND COMPOSITION FOR INHIBITING PGE2, TNF-α, OR IL-1β PRODUCTION INDUCED BY AMYLOID β PEPTIDE
The present invention provides a composition useful in the treatment, prevention, improvement, etc. of Alzheimer's disease, the composition having a component derived from turmeric as an active ingredient. The present invention pertains to a composition for the treatment of Alzheimer's disease, a composition for inhibiting cranial nerve cell death, a composition for inhibiting microglia activation induced by amyloid β peptide, or a composition for inhibiting PGE2, TNF-α, or IL-1β production induced by amyloid β peptide, the composition having as an active ingredient turmeric extract obtained by at least one extraction solvent selected from the group consisting of water and hydrophilic organic solvents, or at least one selected from turmeronol A and turmeronol B.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The purpose of the present invention is to provide a composition which has an anti-inflammatory effect. An anti-inflammatory composition according to the present invention contains a compound represented by formula 1 as an active ingredient. In formula 1, R1 represents a hydrogen atom or a hydroxy group; and A represents a phenyl group which is optionally substituted by a hydroxyl group or a methyl group, or a cyclohexenyl group which is substituted by a hydroxyl group and a methylene group.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 49/248 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
49.
COMPOSITION FOR INHIBITING CANCER CELL PROLIFERATION, ANTI-CANCER COMPOSITION, COMPOSITION FOR INHIBITING CANCERIZATION OF NORMAL CELLS, COMPOSITION FOR INHIBITING CANCER ONSET AND COMPOSITION FOR INDUCING CANCER CELL DEATH
The present invention addresses the problem of inhibiting the cancerization of cells and the progression of cancer malignant alteration, i.e., cancer onset, or inducing cancer cell death. The present invention provides a composition for inhibiting cancer cell proliferation, an anti-cancer composition, a composition for inhibiting cancerization of normal cells, a composition for inhibiting cancer onset, and a composition for inducing cancer cell death, said compositions each comprising, as an active ingredient, at least one among Turmeronol A and Turmeronol B.
The present invention provides a composition having an anti-inflammatory action or a blood CRP value-lowering action, that contains a compound derived from a food material which is highly safe and has a long history of use as a food. The present invention relates to a composition to be taken orally, an anti-inflammatory composition, or a composition for lowering the blood CRP value that contains 100 μg or more of turmeronol A and/or turmeronol B total per intake. The present invention also relates to a composition to be taken orally, an anti-inflammatory composition, or a composition for lowering the blood CRP value that contains 80 μg or more of turmeronol A and/or 20 μg or more of turmeronol B per intake.
A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
51.
COMPOSITION FOR INHIBITING PROLIFERATION OF CANCER CELLS, ANTICANCER COMPOSITION, COMPOSITION FOR PREVENTING CANCERIZATION OF NORMAL CELLS, COMPOSITION FOR PREVENTING CANCER ONSET, AND COMPOSITION FOR INDUCING CANCER CELL DEATH
The present invention addresses the problem of preventing cancerization of cells and malignant progression in cancer, i.e., preventing cancer onset and inducing cell death of cancer cells. Provided are a composition for inhibiting proliferation of cancer cells, an anticancer composition, a composition for preventing cancerization of normal cells, a composition for preventing cancer onset, and a composition for inducing cancer cell death, each composition comprising, as an active ingredient, a turmeric extract containing turmeronol A and turmeronol B which is obtained by extracting turmeric with at least one kind of solvent selected from the group consisting of water and a hydrophilic organic solvent.
The purpose of the present invention is to provide an acidic composition that contains at least one type of vitamin-B-group compound selected from the group that consists of folic acid, vitamin B12, and biotin, the vitamin-B-group compound having excellent stability and/or exhibiting reduced decomposition. An acidic composition that contains the abovementioned vitamin-B-group compound and is characterized by having reduced ethanol content.
The purpose of the present invention is to provide a novel means which enables low-cost refining of bisacurone in high concentration from turmeric. Provided is a manufacturing method for a bisacurone-containing turmeric extract, the method comprising a step for performing stepwise extraction through combinational use, in a prescribed sequence, of a plurality of extraction solvents having different polarity.
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
C07C 45/79 - SeparationPurificationStabilisationUse of additives by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by chemisorption
The purpose of the present invention is to provide a novel means which enables low-cost refining of bisacurone in high concentration from turmeric. Provided is a manufacturing method for a bisacurone-containing turmeric extract, the method comprising a step for performing stepwise extraction through combinational use, in a prescribed sequence, of a plurality of extraction solvents having different polarity.
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
C07C 45/79 - SeparationPurificationStabilisationUse of additives by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by chemisorption
55.
COMPOSITION FOR PROMOTING PRODUCTION OF HYALURONIC ACID
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
Disclosed are methods whereby an effective amount of a HDAC6 inhibitor is used to activate a subjects T-cell response to tumor or tumor vaccine. Methods of using HDAC6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The purpose of the present invention is to provide a composition for preventing, ameliorating or improving metabolic syndrome. The present invention provides a composition for preventing, ameliorating or improving metabolic syndrome, which contains Lactobacillus plantarum L-137.
The purpose of the present invention is to provide a composition which has an anti-inflammatory effect. An anti-inflammatory composition according to the present invention contains a compound represented by formula 1 as an active ingredient. In formula 1, R1 represents a hydrogen atom or a hydroxy group; and A represents a phenyl group which is optionally substituted by a hydroxyl group or a methyl group, or a cyclohexenyl group which is substituted by a hydroxyl group and a methylene group.
An object of the present invention is to provide a low-cost and safe approach to efficient delivery of a substance to phagocytes. In particular, the present invention relates to a carrier for delivery of a substance to phagocytes, the carrier comprising a lactic acid bacterium and/or an extract thereof.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
60.
Composition for prevention, amelioration or treatment of metabolic syndrome
(b) is at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5), are useful for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
The purpose of the present invention is to provide a low-cost and safe means for efficiently transporting a substance to macrophages. A carrier for transporting a substance to macrophages, said carrier being characterized by comprising a lactic acid bacterium and/or an extract thereof.
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
62.
COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF METABOLIC SYNDROME
Disclosed are: a composition comprising the components (a) and (b) mentioned below, wherein the ratio of the component (a) to the component (b) is 1:(0.001 to 5) by mass; and a food, a beverage, a medicinal agent or the like, which contains the composition. The composition and the food, the beverage, the medicinal agent or the like are useful for the prevention, amelioration or treatment of metabolic syndrome, lipid metabolism disorder (e.g., fatty liver, hyperlipemia), obesity (e.g., visceral fat accumulation, subcutaneous fat accumulation), or the like. (a) At least one polyphenol selected from the group consisting of a polyphenol containing 15 mass% or more of a proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin. (b) At least one xanthine derivative.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Lactobacillus plantarum as an active ingredient. The moisturizer of the present invention improves the water retention capacity of the stratum corneum, and is useful for prevention and improvement of rough skin.
The present invention provides a moisturizer comprising, as an active ingredient, a saccharide having 3-O-α-D-glucopyranosyl-D-glucose as a structural unit. The moisturizer of the present invention improves the water retention capacity of the stratum corneum, and is useful for prevention and improvement of rough skin.
A moisturizing agent characterized by containing thermally killed cells of Lactobacillus plantarum as the active ingredient. This moisturizing agent is useful in enhancing the water-retention ability of the horny layer and prevent or ameliorate skin chapping.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The invention is directed to a moisturizing agent characterized by comprising, as an active ingredient, a sugar containing 3-O-&agr;-D-glucopyranosyl-D-glucose as a constituent unit. The moisturizing agent of the invention improves the water retention ability of the stratum corneum and is useful for the prevention of and recovery from skin disorder.
A composition for enhancing an immune function characterized by containing, as the active ingredient, a saccharide having zinc and 3-O-&agr;-D-glucopyranosyl-D-glucose as a constituting unit. This composition for enhancing an immune function exerts an effect of enhancing the immune function that is superior to the effect achieved by using either zinc or 3-O-&agr;-D-glucopyranosyl-D-glucose alone.
patents
